Cancer Vaccines Market
Published date: July 2024 • Report Code: 49712
Request Sample Order This Report
Cancer Vaccines Market

Cancer Vaccines Market Report By Type (Preventive Vaccines [HPV Vaccines (for Cervical Cancer), Hepatitis B Vaccines (for Liver Cancer)], Therapeutic Vaccines [Cancer Treatment Vaccines (e.g., for Prostate Cancer, Melanoma), Personalized Cancer Vaccines], Combination Vaccines [Preventive and Therapeutic]), By Vaccine Type, By Cancer Type, By End-User, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • 49712

  • July 2024

  • 325

  • Format PDF Format XLS Format PPT

    • ★★★★★
      ★★★★★
    • (58)

  • Healthcare

This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page

  • Report Overview

    The Global Cancer Vaccines Market size is expected to be worth around USD 31.8 Billion by 2033, from USD 10.9 Billion in 2023, growing at a CAGR of 11.6% during the forecast period from 2024 to 2033.

    The cancer vaccines market involves vaccines that prevent or treat various types of cancer. These vaccines stimulate the immune system to target cancer cells. Key drivers include increasing cancer prevalence, advancements in immunotherapy, and rising healthcare spending.

    The market is segmented by vaccine type, indication, end-user, and region. Innovations in personalized medicine and combination therapies are influencing market trends. Major players focus on clinical trials, regulatory approvals, and strategic partnerships to bring new vaccines to market and expand their reach in oncology.

    Cancer_Vaccines_Market_By_Size

    The cancer vaccines market is experiencing significant growth, driven by advancements in both preventive and therapeutic vaccines. Preventive vaccines, such as the HPV vaccine, play a crucial role in reducing cancer risk. The Centers for Disease Control and Prevention (CDC) reports that HPV vaccination can prevent over 90% of HPV-related cancers, significantly lowering the incidence of cervical cancer. Similarly, the hepatitis B vaccine is effective in preventing liver cancer, underscoring the importance of vaccines in cancer prevention.

    Therapeutic cancer vaccines are also making strides. These vaccines treat existing cancer by stimulating the immune system to target and destroy cancer cells. Provenge (sipuleucel-T), an FDA-approved therapeutic vaccine for prostate cancer, has shown to improve survival rates. According to the National Cancer Institute (NCI), patients receiving Provenge had a median survival of 25.8 months compared to 21.7 months for those receiving a placebo.

    The market is further bolstered by continuous research and development efforts. Advances in immunotherapy and personalized medicine are paving the way for more effective cancer vaccines. The integration of cutting-edge technologies, such as mRNA platforms, is expected to enhance vaccine efficacy and broaden their application.

    However, the market faces challenges, including high development costs and complex regulatory requirements. Ensuring widespread access to these vaccines, particularly in low-resource settings, remains a critical concern.

    The cancer vaccines market is poised for robust growth. Preventive vaccines like HPV and hepatitis B are essential in reducing cancer incidence, while therapeutic vaccines like Provenge offer new hope for treatment. Ongoing innovation and research will drive the market forward, addressing current challenges and expanding the impact of cancer vaccines.

    Key Takeaways

    • Market Value: The Cancer Vaccines Market was valued at USD 10.9 billion in 2023 and is expected to reach USD 31.8 billion by 2033, with a CAGR of 11.6%.
    • Type Analysis: Preventive Vaccines dominated with 60%; essential for reducing the incidence of certain cancers.
    • Vaccine Type Analysis: Monoclonal Antibodies dominated with 40%; used extensively in targeted cancer therapies.
    • Cancer Type Analysis: Cervical Cancer dominated with 35%; reflecting the effectiveness of HPV vaccines.
    • End-User Analysis: Hospitals dominated with 50%; primary centers for administering cancer vaccines.
    • Dominant Region: North America 40%; due to advanced healthcare infrastructure and high R&D investments.
    • High Growth Region: Europe; expected growth due to supportive regulatory frameworks and increasing awareness of cancer prevention.
    • Analyst Viewpoint: The market is rapidly evolving with continuous advancements in immunotherapy. Future growth will be driven by personalized and combination vaccines.
    • Growth Opportunities: Companies can focus on developing novel vaccines and expanding access to underserved regions to capture market share.

    Driving Factors

    Increasing Cancer Prevalence and Awareness Drives Market Growth

    The rising incidence of various cancers globally is a significant driver for the cancer vaccines market. According to the World Health Organization, cancer is the second leading cause of death worldwide, with an estimated 19.3 million new cases in 2020. This alarming trend has led to increased awareness about cancer prevention and treatment, driving demand for innovative solutions like cancer vaccines.

    For example, the success of HPV vaccines in preventing cervical cancer has heightened interest in developing vaccines for other cancer types. As more people become aware of the benefits of vaccination in cancer prevention, the demand for cancer vaccines grows. This increased awareness, combined with the urgent need to address the rising cancer cases, fuels the market for cancer vaccines.

    Advancements in Immunotherapy and Personalized Medicine Drive Market Growth

    The rapid progress in understanding cancer biology and the immune system has paved the way for more effective cancer vaccines. Personalized cancer vaccines, tailored to an individual's tumor mutations, are showing promising results in clinical trials.

    For instance, Moderna and Merck's personalized mRNA cancer vaccine, when combined with Keytruda, has shown significant potential in treating melanoma patients. This combination demonstrated a 44% reduction in the risk of death or recurrence compared to Keytruda alone. These advancements in immunotherapy and personalized medicine are driving the development and adoption of new cancer vaccines.

    The intersection of cutting-edge research and personalized treatment options enhances the effectiveness of cancer vaccines, supporting their market growth.

    Increased Funding and Investment in Cancer Research Drive Market Growth

    Governments, pharmaceutical companies, and private organizations are allocating substantial resources to cancer vaccine development. The Cancer Moonshot initiative in the United States, which aims to accelerate cancer research, has received a USD 1.8 billion funding boost.

    This influx of capital is driving innovation and accelerating the development of novel cancer vaccines. Increased funding attracts more players to the market, fostering a competitive landscape that encourages growth. The financial support not only facilitates research but also helps bring new vaccines to market faster.

    Restraining Factors

    High Development Costs and Long Approval Processes Restrain Market Growth

    The development of cancer vaccines is an expensive and time-consuming process, often taking over a decade and costing billions of dollars. This significant investment poses a barrier to entry for smaller biotech companies and can slow down innovation.

    For instance, the development of Gardasil, an HPV vaccine that helps prevent certain types of cancer, took Merck over 15 years and cost an estimated USD 1 billion before it reached the market. These high costs and lengthy approval processes deter smaller companies from entering the market, limiting competition and slowing the pace of new vaccine development. Consequently, the overall growth of the cancer vaccines market is restrained by these substantial financial and regulatory hurdles.

    Complex Manufacturing Processes and Scalability Challenges Restrain Market Growth

    Cancer vaccines, especially personalized ones, require sophisticated manufacturing processes that can be difficult to scale up. This complexity can lead to production delays and higher costs, potentially limiting market growth.

    An example is Dendreon's Provenge, which faced significant manufacturing challenges due to its personalized nature, contributing to the company's initial financial struggles despite the vaccine's approval. These production difficulties can delay the availability of vaccines and increase costs, making it challenging to meet market demand efficiently. As a result, the intricate manufacturing and scalability issues inherent in cancer vaccine production hinder the market's expansion.

    Type Analysis

    Preventive Vaccines dominate with 60% due to their effectiveness in preventing HPV and Hepatitis B-related cancers.

    The Cancer Vaccines Market is segmented by type, with Preventive Vaccines leading at 60% market share. This dominance is primarily due to the effectiveness of HPV Vaccines in preventing cervical cancer and Hepatitis B Vaccines in preventing liver cancer. HPV vaccines are widely administered to young females, significantly reducing the incidence of cervical cancer. Similarly, Hepatitis B vaccines have played a crucial role in lowering liver cancer cases by preventing Hepatitis B infection, a major risk factor for liver cancer.

    Therapeutic Vaccines hold a 30% market share. These vaccines are designed to treat existing cancers by stimulating the immune system to attack cancer cells. Cancer Treatment Vaccines, such as those for prostate cancer and melanoma, are part of this segment. These vaccines have shown promising results in prolonging survival and improving the quality of life for cancer patients. Personalized Cancer Vaccines, which are tailored to the individual’s specific cancer profile, represent a growing area within therapeutic vaccines, offering hope for more targeted and effective treatments.

    Combination Vaccines make up the remaining 10%. These vaccines combine preventive and therapeutic approaches, aiming to provide comprehensive cancer control. Although still in early development stages, combination vaccines hold potential for providing broader protection and treatment efficacy, addressing both the prevention of cancer and the treatment of existing cancer cells.

    Vaccine Type Analysis

    Monoclonal Antibodies dominate with 40% due to their targeted approach and effectiveness in cancer treatment.

    In the Cancer Vaccines Market segmented by vaccine type, Monoclonal Antibodies lead with a 40% share. These vaccines work by specifically targeting cancer cells and marking them for destruction by the immune system. Monoclonal antibodies are used in various cancer treatments and have shown significant success in improving patient outcomes. Their ability to target specific antigens on cancer cells while sparing normal cells makes them highly effective and reduces side effects.

    Peptide-Based Vaccines hold a 20% market share. These vaccines use specific peptides to trigger an immune response against cancer cells. They are relatively easy to produce and can be tailored to different types of cancer. Peptide-based vaccines are currently being researched for their potential to treat various cancers, including melanoma and prostate cancer, with some showing promising results in clinical trials.

    DNA-Based Vaccines account for 15% of the market. These vaccines use genetic material to induce an immune response against cancer cells. They are designed to provide long-lasting immunity and have shown potential in preclinical and early clinical studies. DNA-based vaccines are still in the developmental stages but are considered a promising avenue for future cancer treatments.

    RNA-Based Vaccines hold a 10% share. These vaccines use messenger RNA to instruct cells to produce antigens that trigger an immune response. RNA-based vaccines gained attention with the success of COVID-19 vaccines and are now being explored for cancer treatment. Their ability to be quickly designed and manufactured makes them a flexible option for developing new cancer vaccines.

    Protein Subunit Vaccines make up 10% of the market. These vaccines use specific protein fragments from cancer cells to stimulate an immune response. They are considered safe and can be produced relatively easily. Protein subunit vaccines are being researched for various cancers and have shown potential in inducing a robust immune response.

    Cell-Based Vaccines account for the remaining 5%. These vaccines use whole cells, often modified to enhance their ability to stimulate the immune system, to target cancer. They are complex to produce but offer the advantage of presenting multiple antigens to the immune system, potentially improving efficacy. Cell-based vaccines are an area of active research and hold promise for future cancer therapies.

    Cancer Type Analysis

    Cervical Cancer dominates with 35% due to the widespread use of HPV vaccines.

    In the Cancer Vaccines Market segmented by cancer type, Cervical Cancer leads with a 35% share. The widespread use of HPV vaccines has significantly reduced the incidence of cervical cancer, making it the most prominent segment. HPV vaccines are effective in preventing the types of HPV that cause most cervical cancers, leading to high vaccination rates and strong market growth in this area.

    Prostate Cancer holds a 20% market share. Prostate cancer vaccines, including both therapeutic and preventive types, are used to manage and treat this common cancer in men. The demand for effective prostate cancer treatments drives this segment, with ongoing research and clinical trials aimed at improving vaccine efficacy.

    Breast Cancer accounts for 15% of the market. Although there are no widely used preventive vaccines for breast cancer, therapeutic vaccines are being developed and tested. These vaccines aim to stimulate the immune system to target breast cancer cells, providing a new avenue for treatment.

    Lung Cancer holds a 10% share. Lung cancer vaccines are in various stages of development, with some showing promise in clinical trials. The high incidence and mortality rates of lung cancer drive the demand for effective vaccines, making this a critical area of research and development.

    Melanoma makes up 10% of the market. Melanoma vaccines, particularly those using peptide-based or cell-based approaches, are being developed to treat this aggressive form of skin cancer. Early clinical trials have shown promising results, supporting the growth of this segment.

    Bladder Cancer holds 5% of the market. Bladder cancer vaccines are less common but are an area of active research. These vaccines aim to stimulate an immune response against bladder cancer cells, potentially improving treatment outcomes for patients with this type of cancer.

    Other cancers, including those with lower incidence rates or those still in early stages of vaccine development, make up the remaining 5%. Research in these areas continues to explore new ways to use vaccines for cancer prevention and treatment.

    End-User Analysis

    Hospitals dominate with 50% due to their central role in administering cancer treatments and vaccines.

    In the Cancer Vaccines Market segmented by end-user, Hospitals lead with a 50% share. Hospitals are the primary settings for administering cancer treatments and vaccines. They have the necessary infrastructure, medical expertise, and patient care capabilities to deliver complex cancer therapies. The central role of hospitals in patient treatment and care drives their dominance in this market segment.

    Cancer Treatment Centers hold a 25% market share. These specialized centers focus exclusively on cancer diagnostics and treating cancer, including the administration of vaccines. They offer advanced treatment options and often participate in clinical trials for new cancer vaccines. Their specialized focus and expertise in cancer care support their significant market share.

    Research and Academic Institutions account for 15% of the market. These institutions are involved in the development and testing of new cancer vaccines. They conduct clinical trials, perform basic research, and collaborate with pharmaceutical companies to bring new vaccines to market. Their contributions to vaccine development are critical to the overall growth of the cancer vaccine market.

    Pharmaceutical Companies make up the remaining 10%. These companies develop, manufacture, and market cancer vaccines. They invest heavily in research and development to create new vaccines and improve existing ones. Pharmaceutical companies also conduct clinical trials and work to obtain regulatory approvals for their products. Their role in bringing new vaccines to market supports their presence in this segment.

    Cancer_Vaccines_Market_By_Share

    Key Market Segments

    By Type

    • Preventive Vaccines
      • HPV Vaccines (for Cervical Cancer)
      • Hepatitis B Vaccines (for Liver Cancer)
    • Therapeutic Vaccines
      • Cancer Treatment Vaccines (e.g., for Prostate Cancer, Melanoma)
      • Personalized Cancer Vaccines
    • Combination Vaccines
      • Preventive and Therapeutic

    By Vaccine Type

    • Monoclonal Antibodies
    • Peptide-Based Vaccines
    • DNA-Based Vaccines
    • RNA-Based Vaccines
    • Protein Subunit Vaccines
    • Cell-Based Vaccines

    By Cancer Type

    • Breast Cancer
    • Cervical Cancer
    • Prostate Cancer
    • Lung Cancer
    • Melanoma
    • Bladder Cancer
    • Others

    By End-User

    • Hospitals
    • Cancer Treatment Centers
    • Research and Academic Institutions
    • Pharmaceutical Companies

    Growth Opportunities

    Combination Therapies Offer Growth Opportunity

    Combining cancer vaccines with other immunotherapies or traditional treatments offers significant potential for improved efficacy. For example, the combination of cancer vaccines with checkpoint inhibitors has shown promising results in clinical trials, as seen with Moderna and Merck's melanoma vaccine combined with Keytruda.

    This approach can enhance the immune response against cancer cells, leading to better patient outcomes. By exploring combination therapies, the cancer vaccine market can expand its treatment options, improve efficacy rates, and attract investment in research and development, driving market growth.

    Expansion into Preventive Vaccines for Non-Viral Cancers Offers Growth Opportunity

    While HPV vaccines have been successful in preventing cervical cancer, there's an opportunity to develop preventive vaccines for non-viral cancers. Research into vaccines targeting cancer-specific antigens or mutations could lead to a new category of preventive cancer vaccines, potentially revolutionizing cancer prevention strategies.

    By focusing on non-viral cancers, the market can address a broader range of cancers, offering new preventive measures and reducing cancer incidence. This expansion into preventive vaccines for non-viral cancers presents a significant opportunity to advance cancer prevention, attract funding, and drive market growth.

    Trending Factors

    mRNA Technology in Cancer Vaccines Are Trending Factors

    The success of mRNA vaccines for COVID-19 has accelerated interest in using this technology for cancer vaccines. Companies like BioNTech and Moderna are leveraging their mRNA platforms to develop personalized cancer vaccines, with several candidates in clinical trials.

    This technology allows for rapid development and customization of vaccines to target specific cancer types. By utilizing mRNA technology, the cancer vaccine market can advance personalized medicine, enhance treatment effectiveness, and drive significant growth and innovation in cancer therapies.

    Artificial Intelligence in Vaccine Development Are Trending Factors

    AI and machine learning are increasingly being used to accelerate cancer vaccine development. These technologies can help identify potential antigens, predict vaccine efficacy, and optimize clinical trial designs. For instance, Gritstone Oncology uses AI to identify neoantigens for its personalized cancer vaccine candidates.

    The use of AI streamlines the research and development process, making it faster and more efficient. By integrating AI in vaccine development, the cancer vaccine market can improve discovery rates, reduce development costs, and bring effective cancer treatments to market more quickly, driving trends in technological advancement.

    Regional Analysis

    North America Dominates with 40% Market Share in the Cancer Vaccines Market

    North America commands a 40% share of the global cancer vaccines market, driven by advanced biomedical research capabilities and substantial healthcare investments. The region's strong pharmaceutical industry and significant government and private funding for cancer research are pivotal. High public awareness and screening rates also accelerate the adoption of preventive and therapeutic cancer vaccines, boosting market growth.

    The cancer vaccines market in North America benefits from collaborative efforts between research institutions, biotechnology firms, and pharmaceutical companies, which facilitate innovation and rapid development of new vaccines. The prevalence of cancer in the region creates a pressing demand for effective treatments, including vaccines. Furthermore, regulatory support for vaccine approval and a well-established healthcare infrastructure contribute to the vigorous market activity.

    The future of the cancer vaccines market in North America appears strong, with ongoing research into novel vaccine technologies and immunotherapy treatments expected to drive growth. The rising incidence of various cancers and the aging population may further necessitate advancements in vaccine development. North America is likely to maintain or even increase its market share as it continues to lead in innovative cancer treatment solutions.

    Cancer_Vaccines_Market_By_Regional_Analysis

    Regional Market Share and Growth Statistics

    • Europe: Europe holds a 30% share of the market, supported by robust healthcare systems and increasing government funding for cancer research.
    • Asia Pacific: Representing 20% of the market, Asia Pacific's growth is spurred by rising healthcare expenditures and growing awareness of cancer prevention and treatments.
    • Middle East & Africa: This region accounts for 5% of the market. Growth is modest but increasing due to improving healthcare infrastructure and international collaborations in medical research.
    • Latin America: With a 5% market share, Latin America is slowly expanding its focus on healthcare innovations and public health campaigns targeting cancer awareness.

    Key Regions and Countries

    • North America
      • The US
      • Canada
      • Mexico
    • Western Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Portugal
      • Ireland
      • Austria
      • Switzerland
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • The Czech Republic
      • Greece
      • Rest of Eastern Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Australia & New Zealand
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Colombia
      • Chile
      • Argentina
      • Costa Rica
      • Rest of Latin America
    • Middle East & Africa
      • Algeria
      • Egypt
      • Israel
      • Kuwait
      • Nigeria
      • Saudi Arabia
      • South Africa
      • Turkey
      • United Arab Emirates
      • Rest of MEA

    Key Players Analysis

    The cancer vaccines market is dominated by key players with significant impact and strategic positioning. GlaxoSmithKline plc and Merck & Co., Inc. lead with their extensive research and development capabilities. Pfizer Inc. and Sanofi S.A. have strong market presence with their innovative vaccine solutions.

    AstraZeneca plc and Roche Holding AG are recognized for their advanced cancer vaccine research. Moderna, Inc. and Inovio Pharmaceuticals, Inc. leverage cutting-edge technology to develop effective vaccines. Dendreon Pharmaceuticals LLC and Aduro Biotech, Inc. offer specialized cancer vaccines, enhancing their market positions.

    Bavarian Nordic and Agenus Inc. focus on innovative immunotherapy solutions. OncoSec Medical Incorporated and BioNTech SE are key players with strong research and development pipelines. ImmunoCellular Therapeutics, Ltd. provides targeted cancer vaccine solutions.

    These companies use advanced technologies, extensive research, and strong market presence to lead the cancer vaccines market. Their ability to innovate and develop effective vaccines ensures their continued market influence and growth.

    Market Key Players

    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • AstraZeneca plc
    • Roche Holding AG
    • Moderna, Inc.
    • Inovio Pharmaceuticals, Inc.
    • Dendreon Pharmaceuticals LLC
    • Aduro Biotech, Inc.
    • Bavarian Nordic
    • Agenus Inc.
    • OncoSec Medical Incorporated
    • BioNTech SE
    • ImmunoCellular Therapeutics, Ltd.

    Recent Developments

    • Moderna has commenced phase 1/2 clinical trials for its new PD-1/IDO1 cancer vaccine, mRNA-4359. This vaccine targets advanced solid tumors by generating antibodies against PD-L1 and IDO1, with initial treatments starting at Imperial College Healthcare NHS Trust. This trial seeks to evaluate the safety and efficacy of the vaccine combined with other cancer therapies.
    • BioNTech SE, in partnership with Genentech, is testing an mRNA-based colorectal cancer vaccine. The vaccine, developed by analyzing patient-specific tumor mutations, aims to prevent cancer recurrence by stimulating a targeted immune response. This trial is part of a broader effort to provide personalized immunotherapies to up to 10,000 patients by 2030.

    Report Scope

    Report Features Description
    Market Value (2023) USD 10.9 Billion
    Forecast Revenue (2033) USD 31.8 Billion
    CAGR (2024-2033) 11.6%
    Base Year for Estimation 2023
    Historic Period 2018-2023
    Forecast Period 2024-2033
    Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments
    Segments Covered By Type (Preventive Vaccines [HPV Vaccines (for Cervical Cancer), Hepatitis B Vaccines (for Liver Cancer)], Therapeutic Vaccines [Cancer Treatment Vaccines (e.g., for Prostate Cancer, Melanoma), Personalized Cancer Vaccines], Combination Vaccines [Preventive and Therapeutic]), By Vaccine Type (Monoclonal Antibodies, Peptide-Based Vaccines, DNA-Based Vaccines, RNA-Based Vaccines, Protein Subunit Vaccines, Cell-Based Vaccines), By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Melanoma, Bladder Cancer, Others), By End-User (Hospitals, Cancer Treatment Centers, Research and Academic Institutions, Pharmaceutical Companies)
    Regional Analysis North America - The US, Canada, & Mexico; Western Europe - Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe - Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC - China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America - Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa - Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., AstraZeneca plc, Roche Holding AG, Moderna, Inc., Inovio Pharmaceuticals, Inc., Dendreon Pharmaceuticals LLC, Aduro Biotech, Inc., Bavarian Nordic, Agenus Inc., OncoSec Medical Incorporated, BioNTech SE, ImmunoCellular Therapeutics, Ltd.
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
      • 1.4. Key Analysis
      • 1.5. Key Findings by Major Segments
      • 1.6. Top strategies by Major Players
    • 2. Global Cancer Vaccines Market Overview
      • 2.1. Cancer Vaccines Market Dynamics
        • 2.1.1. Drivers
        • 2.1.2. Opportunities
        • 2.1.3. Restraints
        • 2.1.4. Challenges
      • 2.2. Macro-economic Factors
      • 2.3. Regulatory Framework
      • 2.4. Market Investment Feasibility Index
      • 2.5. PEST Analysis
      • 2.6. PORTER’S Five Force Analysis
      • 2.7. Drivers & Restraints Impact Analysis
      • 2.8. Industry Chain Analysis
      • 2.9. Cost Structure Analysis
      • 2.10. Marketing Strategy
      • 2.11. Russia-Ukraine War Impact Analysis
      • 2.12. Opportunity Map Analysis
      • 2.13. Market Competition Scenario Analysis
      • 2.14. Product Life Cycle Analysis
      • 2.15. Opportunity Orbits
      • 2.16. Manufacturer Intensity Map
      • 2.17. Major Companies sales by Value & Volume
    • 3. Global Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 3.1. Global Cancer Vaccines Market Analysis, 2016-2021
      • 3.2. Global Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 3.3. Global Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 3.3.1. Global Cancer Vaccines Market Analysis by Type: Introduction
        • 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 3.3.3. Preventive Vaccines
        • 3.3.4. Therapeutic Vaccines
        • 3.3.5. Combination Vaccines
      • 3.4. Global Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 3.4.1. Global Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 3.4.3. Monoclonal Antibodies
        • 3.4.4. Peptide-Based Vaccines
        • 3.4.5. DNA-Based Vaccines
        • 3.4.6. RNA-Based Vaccines
        • 3.4.7. Protein Subunit Vaccines
        • 3.4.8. Cell-Based Vaccines
      • 3.5. Global Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 3.5.1. Global Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 3.5.3. Breast Cancer
        • 3.5.4. Cervical Cancer
        • 3.5.5. Prostate Cancer
        • 3.5.6. Lung Cancer
        • 3.5.7. Melanoma
        • 3.5.8. Bladder Cancer
        • 3.5.9. Others
      • 3.6. Global Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 3.6.1. Global Cancer Vaccines Market Analysis by End-User: Introduction
        • 3.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 3.6.3. Hospitals
        • 3.6.4. Cancer Treatment Centers
        • 3.6.5. Research and Academic Institutions
        • 3.6.6. Pharmaceutical Companies
    • 4. North America Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 4.1. North America Cancer Vaccines Market Analysis, 2016-2021
      • 4.2. North America Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 4.3. North America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 4.3.1. North America Cancer Vaccines Market Analysis by Type: Introduction
        • 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 4.3.3. Preventive Vaccines
        • 4.3.4. Therapeutic Vaccines
        • 4.3.5. Combination Vaccines
      • 4.4. North America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 4.4.1. North America Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 4.4.3. Monoclonal Antibodies
        • 4.4.4. Peptide-Based Vaccines
        • 4.4.5. DNA-Based Vaccines
        • 4.4.6. RNA-Based Vaccines
        • 4.4.7. Protein Subunit Vaccines
        • 4.4.8. Cell-Based Vaccines
      • 4.5. North America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 4.5.1. North America Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 4.5.3. Breast Cancer
        • 4.5.4. Cervical Cancer
        • 4.5.5. Prostate Cancer
        • 4.5.6. Lung Cancer
        • 4.5.7. Melanoma
        • 4.5.8. Bladder Cancer
        • 4.5.9. Others
      • 4.6. North America Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 4.6.1. North America Cancer Vaccines Market Analysis by End-User: Introduction
        • 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 4.6.3. Hospitals
        • 4.6.4. Cancer Treatment Centers
        • 4.6.5. Research and Academic Institutions
        • 4.6.6. Pharmaceutical Companies
      • 4.7. North America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 4.7.1. North America Cancer Vaccines Market Analysis by Country : Introduction
        • 4.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 4.7.2.1. The US
          • 4.7.2.2. Canada
          • 4.7.2.3. Mexico
    • 5. Western Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 5.1. Western Europe Cancer Vaccines Market Analysis, 2016-2021
      • 5.2. Western Europe Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 5.3. Western Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 5.3.1. Western Europe Cancer Vaccines Market Analysis by Type: Introduction
        • 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 5.3.3. Preventive Vaccines
        • 5.3.4. Therapeutic Vaccines
        • 5.3.5. Combination Vaccines
      • 5.4. Western Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 5.4.1. Western Europe Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 5.4.3. Monoclonal Antibodies
        • 5.4.4. Peptide-Based Vaccines
        • 5.4.5. DNA-Based Vaccines
        • 5.4.6. RNA-Based Vaccines
        • 5.4.7. Protein Subunit Vaccines
        • 5.4.8. Cell-Based Vaccines
      • 5.5. Western Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 5.5.1. Western Europe Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 5.5.3. Breast Cancer
        • 5.5.4. Cervical Cancer
        • 5.5.5. Prostate Cancer
        • 5.5.6. Lung Cancer
        • 5.5.7. Melanoma
        • 5.5.8. Bladder Cancer
        • 5.5.9. Others
      • 5.6. Western Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 5.6.1. Western Europe Cancer Vaccines Market Analysis by End-User: Introduction
        • 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 5.6.3. Hospitals
        • 5.6.4. Cancer Treatment Centers
        • 5.6.5. Research and Academic Institutions
        • 5.6.6. Pharmaceutical Companies
      • 5.7. Western Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 5.7.1. Western Europe Cancer Vaccines Market Analysis by Country : Introduction
        • 5.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 5.7.2.1. Germany
          • 5.7.2.2. France
          • 5.7.2.3. The UK
          • 5.7.2.4. Spain
          • 5.7.2.5. Italy
          • 5.7.2.6. Portugal
          • 5.7.2.7. Ireland
          • 5.7.2.8. Austria
          • 5.7.2.9. Switzerland
          • 5.7.2.10. Benelux
          • 5.7.2.11. Nordic
          • 5.7.2.12. Rest of Western Europe
    • 6. Eastern Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 6.1. Eastern Europe Cancer Vaccines Market Analysis, 2016-2021
      • 6.2. Eastern Europe Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 6.3. Eastern Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 6.3.1. Eastern Europe Cancer Vaccines Market Analysis by Type: Introduction
        • 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 6.3.3. Preventive Vaccines
        • 6.3.4. Therapeutic Vaccines
        • 6.3.5. Combination Vaccines
      • 6.4. Eastern Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 6.4.1. Eastern Europe Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 6.4.3. Monoclonal Antibodies
        • 6.4.4. Peptide-Based Vaccines
        • 6.4.5. DNA-Based Vaccines
        • 6.4.6. RNA-Based Vaccines
        • 6.4.7. Protein Subunit Vaccines
        • 6.4.8. Cell-Based Vaccines
      • 6.5. Eastern Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 6.5.1. Eastern Europe Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 6.5.3. Breast Cancer
        • 6.5.4. Cervical Cancer
        • 6.5.5. Prostate Cancer
        • 6.5.6. Lung Cancer
        • 6.5.7. Melanoma
        • 6.5.8. Bladder Cancer
        • 6.5.9. Others
      • 6.6. Eastern Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 6.6.1. Eastern Europe Cancer Vaccines Market Analysis by End-User: Introduction
        • 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 6.6.3. Hospitals
        • 6.6.4. Cancer Treatment Centers
        • 6.6.5. Research and Academic Institutions
        • 6.6.6. Pharmaceutical Companies
      • 6.7. Eastern Europe Cancer Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 6.7.1. Eastern Europe Cancer Vaccines Market Analysis by Country : Introduction
        • 6.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 6.7.2.1. Russia
          • 6.7.2.2. Poland
          • 6.7.2.3. The Czech Republic
          • 6.7.2.4. Greece
          • 6.7.2.5. Rest of Eastern Europe
    • 7. APAC Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 7.1. APAC Cancer Vaccines Market Analysis, 2016-2021
      • 7.2. APAC Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 7.3. APAC Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 7.3.1. APAC Cancer Vaccines Market Analysis by Type: Introduction
        • 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 7.3.3. Preventive Vaccines
        • 7.3.4. Therapeutic Vaccines
        • 7.3.5. Combination Vaccines
      • 7.4. APAC Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 7.4.1. APAC Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 7.4.3. Monoclonal Antibodies
        • 7.4.4. Peptide-Based Vaccines
        • 7.4.5. DNA-Based Vaccines
        • 7.4.6. RNA-Based Vaccines
        • 7.4.7. Protein Subunit Vaccines
        • 7.4.8. Cell-Based Vaccines
      • 7.5. APAC Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 7.5.1. APAC Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 7.5.3. Breast Cancer
        • 7.5.4. Cervical Cancer
        • 7.5.5. Prostate Cancer
        • 7.5.6. Lung Cancer
        • 7.5.7. Melanoma
        • 7.5.8. Bladder Cancer
        • 7.5.9. Others
      • 7.6. APAC Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 7.6.1. APAC Cancer Vaccines Market Analysis by End-User: Introduction
        • 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 7.6.3. Hospitals
        • 7.6.4. Cancer Treatment Centers
        • 7.6.5. Research and Academic Institutions
        • 7.6.6. Pharmaceutical Companies
      • 7.7. APAC Cancer Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 7.7.1. APAC Cancer Vaccines Market Analysis by Country : Introduction
        • 7.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 7.7.2.1. China
          • 7.7.2.2. Japan
          • 7.7.2.3. South Korea
          • 7.7.2.4. India
          • 7.7.2.5. Australia & New Zeland
          • 7.7.2.6. Indonesia
          • 7.7.2.7. Malaysia
          • 7.7.2.8. Philippines
          • 7.7.2.9. Singapore
          • 7.7.2.10. Thailand
          • 7.7.2.11. Vietnam
          • 7.7.2.12. Rest of APAC
    • 8. Latin America Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 8.1. Latin America Cancer Vaccines Market Analysis, 2016-2021
      • 8.2. Latin America Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 8.3. Latin America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 8.3.1. Latin America Cancer Vaccines Market Analysis by Type: Introduction
        • 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 8.3.3. Preventive Vaccines
        • 8.3.4. Therapeutic Vaccines
        • 8.3.5. Combination Vaccines
      • 8.4. Latin America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 8.4.1. Latin America Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 8.4.3. Monoclonal Antibodies
        • 8.4.4. Peptide-Based Vaccines
        • 8.4.5. DNA-Based Vaccines
        • 8.4.6. RNA-Based Vaccines
        • 8.4.7. Protein Subunit Vaccines
        • 8.4.8. Cell-Based Vaccines
      • 8.5. Latin America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 8.5.1. Latin America Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 8.5.3. Breast Cancer
        • 8.5.4. Cervical Cancer
        • 8.5.5. Prostate Cancer
        • 8.5.6. Lung Cancer
        • 8.5.7. Melanoma
        • 8.5.8. Bladder Cancer
        • 8.5.9. Others
      • 8.6. Latin America Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 8.6.1. Latin America Cancer Vaccines Market Analysis by End-User: Introduction
        • 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 8.6.3. Hospitals
        • 8.6.4. Cancer Treatment Centers
        • 8.6.5. Research and Academic Institutions
        • 8.6.6. Pharmaceutical Companies
      • 8.7. Latin America Cancer Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 8.7.1. Latin America Cancer Vaccines Market Analysis by Country : Introduction
        • 8.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 8.7.2.1. Brazil
          • 8.7.2.2. Colombia
          • 8.7.2.3. Chile
          • 8.7.2.4. Argentina
          • 8.7.2.5. Costa Rica
          • 8.7.2.6. Rest of Latin America
    • 9. Middle East & Africa Cancer Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
      • 9.1. Middle East & Africa Cancer Vaccines Market Analysis, 2016-2021
      • 9.2. Middle East & Africa Cancer Vaccines Market Opportunity and Forecast, 2023-2032
      • 9.3. Middle East & Africa Cancer Vaccines Market Analysis, Opportunity and Forecast, By Type, 2016-2032
        • 9.3.1. Middle East & Africa Cancer Vaccines Market Analysis by Type: Introduction
        • 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Type, 2016-2032
        • 9.3.3. Preventive Vaccines
        • 9.3.4. Therapeutic Vaccines
        • 9.3.5. Combination Vaccines
      • 9.4. Middle East & Africa Cancer Vaccines Market Analysis, Opportunity and Forecast, By Vaccine Type, 2016-2032
        • 9.4.1. Middle East & Africa Cancer Vaccines Market Analysis by Vaccine Type: Introduction
        • 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Vaccine Type, 2016-2032
        • 9.4.3. Monoclonal Antibodies
        • 9.4.4. Peptide-Based Vaccines
        • 9.4.5. DNA-Based Vaccines
        • 9.4.6. RNA-Based Vaccines
        • 9.4.7. Protein Subunit Vaccines
        • 9.4.8. Cell-Based Vaccines
      • 9.5. Middle East & Africa Cancer Vaccines Market Analysis, Opportunity and Forecast, By Cancer Type, 2016-2032
        • 9.5.1. Middle East & Africa Cancer Vaccines Market Analysis by Cancer Type: Introduction
        • 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Cancer Type, 2016-2032
        • 9.5.3. Breast Cancer
        • 9.5.4. Cervical Cancer
        • 9.5.5. Prostate Cancer
        • 9.5.6. Lung Cancer
        • 9.5.7. Melanoma
        • 9.5.8. Bladder Cancer
        • 9.5.9. Others
      • 9.6. Middle East & Africa Cancer Vaccines Market Analysis, Opportunity and Forecast, By End-User, 2016-2032
        • 9.6.1. Middle East & Africa Cancer Vaccines Market Analysis by End-User: Introduction
        • 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-User, 2016-2032
        • 9.6.3. Hospitals
        • 9.6.4. Cancer Treatment Centers
        • 9.6.5. Research and Academic Institutions
        • 9.6.6. Pharmaceutical Companies
      • 9.7. Middle East & Africa Cancer Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 9.7.1. Middle East & Africa Cancer Vaccines Market Analysis by Country : Introduction
        • 9.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 9.7.2.1. Algeria
          • 9.7.2.2. Egypt
          • 9.7.2.3. Israel
          • 9.7.2.4. Kuwait
          • 9.7.2.5. Nigeria
          • 9.7.2.6. Saudi Arabia
          • 9.7.2.7. South Africa
          • 9.7.2.8. Turkey
          • 9.7.2.9. The UAE
          • 9.7.2.10. Rest of MEA
    • 10. Global Cancer Vaccines Market Analysis, Opportunity and Forecast, By Region , 2016-2032
      • 10.1. Global Cancer Vaccines Market Analysis by Region : Introduction
      • 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
        • 10.2.1. North America
        • 10.2.2. Western Europe
        • 10.2.3. Eastern Europe
        • 10.2.4. APAC
        • 10.2.5. Latin America
        • 10.2.6. Middle East & Africa
    • 11. Global Cancer Vaccines Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 11.1. Market Share Analysis
      • 11.2. Company Profiles
      • 11.3. GlaxoSmithKline plc
        • 11.3.1. Company Overview
        • 11.3.2. Financial Highlights
        • 11.3.3. Product Portfolio
        • 11.3.4. SWOT Analysis
        • 11.3.5. Key Strategies and Developments
      • 11.4. Merck & Co., Inc.
        • 11.4.1. Company Overview
        • 11.4.2. Financial Highlights
        • 11.4.3. Product Portfolio
        • 11.4.4. SWOT Analysis
        • 11.4.5. Key Strategies and Developments
      • 11.5. Pfizer Inc.
        • 11.5.1. Company Overview
        • 11.5.2. Financial Highlights
        • 11.5.3. Product Portfolio
        • 11.5.4. SWOT Analysis
        • 11.5.5. Key Strategies and Developments
      • 11.6. Sanofi S.A.
        • 11.6.1. Company Overview
        • 11.6.2. Financial Highlights
        • 11.6.3. Product Portfolio
        • 11.6.4. SWOT Analysis
        • 11.6.5. Key Strategies and Developments
      • 11.7. AstraZeneca plc
        • 11.7.1. Company Overview
        • 11.7.2. Financial Highlights
        • 11.7.3. Product Portfolio
        • 11.7.4. SWOT Analysis
        • 11.7.5. Key Strategies and Developments
      • 11.8. Roche Holding AG
        • 11.8.1. Company Overview
        • 11.8.2. Financial Highlights
        • 11.8.3. Product Portfolio
        • 11.8.4. SWOT Analysis
        • 11.8.5. Key Strategies and Developments
      • 11.9. Moderna, Inc.
        • 11.9.1. Company Overview
        • 11.9.2. Financial Highlights
        • 11.9.3. Product Portfolio
        • 11.9.4. SWOT Analysis
        • 11.9.5. Key Strategies and Developments
      • 11.10. Inovio Pharmaceuticals, Inc.
        • 11.10.1. Company Overview
        • 11.10.2. Financial Highlights
        • 11.10.3. Product Portfolio
        • 11.10.4. SWOT Analysis
        • 11.10.5. Key Strategies and Developments
      • 11.11. Dendreon Pharmaceuticals LLC
        • 11.11.1. Company Overview
        • 11.11.2. Financial Highlights
        • 11.11.3. Product Portfolio
        • 11.11.4. SWOT Analysis
        • 11.11.5. Key Strategies and Developments
      • 11.12. Aduro Biotech, Inc.
        • 11.12.1. Company Overview
        • 11.12.2. Financial Highlights
        • 11.12.3. Product Portfolio
        • 11.12.4. SWOT Analysis
        • 11.12.5. Key Strategies and Developments
        • 11.13.1. Company Overview
        • 11.13.2. Financial Highlights
        • 11.13.3. Product Portfolio
        • 11.13.4. SWOT Analysis
        • 11.13.5. Key Strategies and Developments
      • 11.14. Bavarian Nordic
        • 11.14.1. Company Overview
        • 11.14.2. Financial Highlights
        • 11.14.3. Product Portfolio
        • 11.14.4. SWOT Analysis
        • 11.14.5. Key Strategies and Developments
      • 11.15. OncoSec Medical Incorporated
        • 11.15.1. Company Overview
        • 11.15.2. Financial Highlights
        • 11.15.3. Product Portfolio
        • 11.15.4. SWOT Analysis
        • 11.15.5. Key Strategies and Developments
      • 11.16. BioNTech SE
        • 11.16.1. Company Overview
        • 11.16.2. Financial Highlights
        • 11.16.3. Product Portfolio
        • 11.16.4. SWOT Analysis
        • 11.16.5. Key Strategies and Developments
      • 11.17. ImmunoCellular Therapeutics, Ltd.
        • 11.17.1. Company Overview
        • 11.17.2. Financial Highlights
        • 11.17.3. Product Portfolio
        • 11.17.4. SWOT Analysis
        • 11.17.5. Key Strategies and Developments
    • 12. Assumptions and Acronyms
    • 13. Research Methodology
    • 14. Contact

    "

    • List of Figures
        "

      • Figure 1: Global Cancer Vaccines Market Revenue (US$ Mn) Market Share by Type in 2022
      • Figure 2: Global Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 3: Global Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 4: Global Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 5: Global Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 6: Global Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 7: Global Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 8: Global Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 9: Global Cancer Vaccines Market Revenue (US$ Mn) Market Share by Region in 2022
      • Figure 10: Global Cancer Vaccines Market Attractiveness Analysis by Region, 2016-2032
      • Figure 11: Global Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 12: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Figure 13: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 14: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 15: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 16: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 17: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Figure 18: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 19: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 20: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 21: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 22: Global Cancer Vaccines Market Share Comparison by Region (2016-2032)
      • Figure 23: Global Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 24: Global Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 25: Global Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 26: Global Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Figure 27: North America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Typein 2022
      • Figure 28: North America Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 29: North America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 30: North America Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 31: North America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 32: North America Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 33: North America Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 34: North America Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 35: North America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 36: North America Cancer Vaccines Market Attractiveness Analysis by Country, 2016-2032
      • Figure 37: North America Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 38: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 39: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 40: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 41: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 42: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 43: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 44: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 45: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 46: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 47: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 48: North America Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Figure 49: North America Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 50: North America Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 51: North America Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 52: North America Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Figure 53: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Typein 2022
      • Figure 54: Western Europe Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 55: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 56: Western Europe Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 57: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 58: Western Europe Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 59: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 60: Western Europe Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 61: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 62: Western Europe Cancer Vaccines Market Attractiveness Analysis by Country, 2016-2032
      • Figure 63: Western Europe Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 64: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 65: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 66: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 67: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 68: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 69: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 70: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 71: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 72: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 73: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 74: Western Europe Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Figure 75: Western Europe Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 76: Western Europe Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 77: Western Europe Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 78: Western Europe Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Figure 79: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Typein 2022
      • Figure 80: Eastern Europe Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 81: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 82: Eastern Europe Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 83: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 84: Eastern Europe Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 85: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 86: Eastern Europe Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 87: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 88: Eastern Europe Cancer Vaccines Market Attractiveness Analysis by Country, 2016-2032
      • Figure 89: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 90: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 91: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 92: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 93: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 94: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 95: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 96: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 97: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 98: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 99: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 100: Eastern Europe Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Figure 101: Eastern Europe Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 102: Eastern Europe Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 103: Eastern Europe Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 104: Eastern Europe Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Figure 105: APAC Cancer Vaccines Market Revenue (US$ Mn) Market Share by Typein 2022
      • Figure 106: APAC Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 107: APAC Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 108: APAC Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 109: APAC Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 110: APAC Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 111: APAC Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 112: APAC Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 113: APAC Cancer Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 114: APAC Cancer Vaccines Market Attractiveness Analysis by Country, 2016-2032
      • Figure 115: APAC Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 116: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 117: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 118: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 119: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 120: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 121: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 122: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 123: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 124: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 125: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 126: APAC Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Figure 127: APAC Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 128: APAC Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 129: APAC Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 130: APAC Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Figure 131: Latin America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Typein 2022
      • Figure 132: Latin America Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 133: Latin America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 134: Latin America Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 135: Latin America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 136: Latin America Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 137: Latin America Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 138: Latin America Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 139: Latin America Cancer Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 140: Latin America Cancer Vaccines Market Attractiveness Analysis by Country, 2016-2032
      • Figure 141: Latin America Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 142: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 143: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 144: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 145: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 146: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 147: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 148: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 149: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 150: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 151: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 152: Latin America Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Figure 153: Latin America Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 154: Latin America Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 155: Latin America Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 156: Latin America Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Figure 157: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Market Share by Typein 2022
      • Figure 158: Middle East & Africa Cancer Vaccines Market Attractiveness Analysis by Type, 2016-2032
      • Figure 159: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Market Share by Vaccine Typein 2022
      • Figure 160: Middle East & Africa Cancer Vaccines Market Attractiveness Analysis by Vaccine Type, 2016-2032
      • Figure 161: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Market Share by Cancer Typein 2022
      • Figure 162: Middle East & Africa Cancer Vaccines Market Attractiveness Analysis by Cancer Type, 2016-2032
      • Figure 163: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Market Share by End-Userin 2022
      • Figure 164: Middle East & Africa Cancer Vaccines Market Attractiveness Analysis by End-User, 2016-2032
      • Figure 165: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 166: Middle East & Africa Cancer Vaccines Market Attractiveness Analysis by Country, 2016-2032
      • Figure 167: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Figure 168: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 169: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Figure 170: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Figure 171: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Figure 172: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Figure 173: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 174: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Figure 175: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Figure 176: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Figure 177: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Figure 178: Middle East & Africa Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Figure 179: Middle East & Africa Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Figure 180: Middle East & Africa Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Figure 181: Middle East & Africa Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Figure 182: Middle East & Africa Cancer Vaccines Market Share Comparison by End-User (2016-2032)

      "

    • List of Tables
        "

      • Table 1: Global Cancer Vaccines Market Comparison by Type (2016-2032)
      • Table 2: Global Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 3: Global Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 4: Global Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 5: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 6: Global Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 7: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 8: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 9: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 10: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 11: Global Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 12: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Table 13: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 14: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 15: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 16: Global Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 17: Global Cancer Vaccines Market Share Comparison by Region (2016-2032)
      • Table 18: Global Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 19: Global Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 20: Global Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 21: Global Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Table 22: North America Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 23: North America Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 24: North America Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 25: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 26: North America Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 27: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 28: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 29: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 30: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 31: North America Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 32: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 33: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 34: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 35: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 36: North America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 37: North America Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Table 38: North America Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 39: North America Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 40: North America Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 41: North America Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Table 42: Western Europe Cancer Vaccines Market Comparison by Type (2016-2032)
      • Table 43: Western Europe Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 44: Western Europe Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 45: Western Europe Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 46: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 47: Western Europe Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 48: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 49: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 50: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 51: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 52: Western Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 53: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 54: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 55: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 56: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 57: Western Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 58: Western Europe Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Table 59: Western Europe Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 60: Western Europe Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 61: Western Europe Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 62: Western Europe Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Table 63: Eastern Europe Cancer Vaccines Market Comparison by Type (2016-2032)
      • Table 64: Eastern Europe Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 65: Eastern Europe Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 66: Eastern Europe Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 67: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 68: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 69: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 70: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 71: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 72: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 73: Eastern Europe Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 74: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 75: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 76: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 77: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 78: Eastern Europe Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 79: Eastern Europe Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Table 80: Eastern Europe Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 81: Eastern Europe Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 82: Eastern Europe Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 83: Eastern Europe Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Table 84: APAC Cancer Vaccines Market Comparison by Type (2016-2032)
      • Table 85: APAC Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 86: APAC Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 87: APAC Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 88: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 89: APAC Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 90: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 91: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 92: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 93: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 94: APAC Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 95: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 96: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 97: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 98: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 99: APAC Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 100: APAC Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Table 101: APAC Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 102: APAC Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 103: APAC Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 104: APAC Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Table 105: Latin America Cancer Vaccines Market Comparison by Type (2016-2032)
      • Table 106: Latin America Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 107: Latin America Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 108: Latin America Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 109: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 110: Latin America Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 111: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 112: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 113: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 114: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 115: Latin America Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 116: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 117: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 118: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 119: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 120: Latin America Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 121: Latin America Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Table 122: Latin America Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 123: Latin America Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 124: Latin America Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 125: Latin America Cancer Vaccines Market Share Comparison by End-User (2016-2032)
      • Table 126: Middle East & Africa Cancer Vaccines Market Comparison by Type (2016-2032)
      • Table 127: Middle East & Africa Cancer Vaccines Market Comparison by Vaccine Type (2016-2032)
      • Table 128: Middle East & Africa Cancer Vaccines Market Comparison by Cancer Type (2016-2032)
      • Table 129: Middle East & Africa Cancer Vaccines Market Comparison by End-User (2016-2032)
      • Table 130: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 131: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) (2016-2032)
      • Table 132: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 133: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Type (2016-2032)
      • Table 134: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Vaccine Type (2016-2032)
      • Table 135: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by Cancer Type (2016-2032)
      • Table 136: Middle East & Africa Cancer Vaccines Market Revenue (US$ Mn) Comparison by End-User (2016-2032)
      • Table 137: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 138: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Type (2016-2032)
      • Table 139: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Vaccine Type (2016-2032)
      • Table 140: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by Cancer Type (2016-2032)
      • Table 141: Middle East & Africa Cancer Vaccines Market Y-o-Y Growth Rate Comparison by End-User (2016-2032)
      • Table 142: Middle East & Africa Cancer Vaccines Market Share Comparison by Country (2016-2032)
      • Table 143: Middle East & Africa Cancer Vaccines Market Share Comparison by Type (2016-2032)
      • Table 144: Middle East & Africa Cancer Vaccines Market Share Comparison by Vaccine Type (2016-2032)
      • Table 145: Middle East & Africa Cancer Vaccines Market Share Comparison by Cancer Type (2016-2032)
      • Table 146: Middle East & Africa Cancer Vaccines Market Share Comparison by End-User (2016-2032)
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • AstraZeneca plc
    • Roche Holding AG
    • Moderna, Inc.
    • Inovio Pharmaceuticals, Inc.
    • Dendreon Pharmaceuticals LLC
    • Aduro Biotech, Inc.
    • Bavarian Nordic
    • Agenus Inc.
    • OncoSec Medical Incorporated
    • BioNTech SE
    • ImmunoCellular Therapeutics, Ltd.
✖
Request a Sample Report
We'll get back to you as quickly as possible

Wnat a quick look at the report?
Request Sample
Do you have a query?
Speak with analyst
Need personalized modifications?
Customize Report

Our Clients

  • Our Clients
    Our Clients

View Our Licence Options

Order This Report
Report Methodology Research Methodology
LOOKING FOR A PERSONALIZED REPORT?
Our team specializes in tailoring reports to your specific needs, and the best part? It's absolutely free. Whether you require standalone sections, country-level analysis, or discounts tailored for start-ups and universities, we've got you covered.
Request for Customization

MARKET RESEARCH REPORTS

MarketResearch.biz (Powered by Prudour Pvt. Ltd.) delivers customized research solutions by actuating its broad spectrum of research methodologies, databases, and resources, and this is further strengthened by our global experience in syndicated and customized industry projects.

Our tailor-made research services include quick market scans, country reports, in-depth market analysis, competition monitoring, consumer research and satisfaction studies, supplier research, growth planning, and quite a lot more.

SHORT NAVIGATION

CONTACT US